Biocon's subsidiary, Biocon Biologics, has introduced Nepexto, a biosimilar to Enbrel (Etanercept), in Australia for treating ...

Biocon Biologics launches Nepexto, a biosimilar for autoimmune diseases like rheumatoid arthritis, in Australia. The drug ...

Biocon Biologics, a subsidiary of Biocon, has introduced Nepexto, a biosimilar to Enbrel, in the Australian market for ...

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced it ...

Biocon advanced 1.34% to Rs 392.25 after the company said that Biocon Biologics (BBL) has launched Nepexto, a biosimilar to the reference product Enbrel (Etanercept), in Australia.

Etanercept is a TNF (tumor necrosis factor) inhibitor used to treat several autoimmune conditions, including rheumatoid ...

Biocon Biologics (BBL), a fully integrated global biosimilars company and subsidiary of Biocon, announced today it has launched Nepexto, a biosimilar to the reference product Enbrel (Etanercept), in ...

The shares of biopharmaceutical firm Biocon fell as much as 2.04 per cent in Tuesday's trading session, figuring among top ...

India is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expirations of blockbuster drugs. Pharmaceutical giants are ...